Burkly Linda sold $2K of EDIT

Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 709 shares of Editas Medicine, Inc. (EDIT) at $3.04 on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burkly Linda
Published Sep 4, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
high confidence
Mentioned
$EDIT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock, but it adds to the transparency of insider activity.

02

Market read

Routine insider sale with minimal trading relevance.

03

What to watch

Potential upcoming clinical data releases could change insider behavior.

Relevance 2/10Novelty 2/10Timing: post‑market 2026‑09‑03

Background

Editas Medicine is a CRISPR gene‑editing biotech; insider transactions are routinely reported via Form 4.

Company-level read

Ticker impact

$EDITNeutralHigh confidence
Context

Form 4 disclosed a 709‑share sale by EVP/CSO for $2,153, a routine insider transaction.

Expected impact

No material price movement expected.

Evidence & confidence

Sale size is small relative to float and disclosed via pre‑arranged 10b5‑1 plan.

Market effects

None; biotech sector not affected by a micro insider sale.

None; US market impact negligible.

None

Counterpoint

Even small insider sells can signal confidence issues; monitor for further disposals.

Key entities

  • Burkly Linda

    EVP, Chief Scientific Officer at Editas Medicine.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EDITMed

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.